PurISTSM test, now commercially available through Tempus for clinical use, identifies the molecular subtype of patients with unresectable stage III or stage IV pancreatic ductal adenocarcinoma (PDAC).
PurIST utilizes RNA sequencing information to classify patients with PDAC into either a basal or classical subtype, and may help guide clinical management. Patients with a classical subtype were found to have an overall better prognosis and superior median overall survival when treated with first-line FOLFIRINOX, compared to patients with a basal subtype. (Rashid NU et al.,2020; Wenric S, et al.,2023)
- Rashid NU et al. Purity independent subtyping of tumors (PurIST), a clinically robust, single-sample classifier for tumor subtyping in pancreatic cancer. Clinical Cancer Research. 2020;26(1):82-92. doi: 10.1158/1078-0432.CCR-19-1467
- Wenric S, Davison JM, Guittar J, et al. Real-world data validation of the purist pancreatic ductal adenocarcinoma gene expression classifier and its prognostic implications. medRxiv. Preprint posted online February 24, 2023. doi:10.1101/2023.02.23.23286356